摘要
To investigate the anti-angiogenesis action of Taohong Siwu Decoction Ⅱ(THSWD Ⅱ).Methods:The chick chorioallantoic membrane(CAM)assay was adopted to study the anti-angiogenesis action ofTHSWD Ⅱ;the MTT test was used to investigate its effect on proliferation of the human umbilical veinendothelial cells ECV304;and the immunohistochemical method was used to observe the effect of THSWDⅡ on the expression of kinase insert domain containing receptor/fetal liver kinase 1(KDR/FIk-1)and the.microvessel density(MVD)of B 16 melanoma in mice.Results:After treatment with THSWD Ⅱ,the bloodvessel index of CAM and the absorbency of ECV304 in the THSWD Ⅱ 1mg/ml group and the 2mg/mlgroup decreased significantly(P<0.01);the weight,the expression of KDR/Flk-1 and the MVD of B 16melanoma in mice reduced significantly in the THSWD Ⅱ 5g/kg group,the 10g/kg group and theTSHSWD10g/kg plus cyclophosphamide group(P<0.01).Conclusion:THSWD Ⅱ has the actions ofanti-angiogenesis,and inhibiting the proliferation of ECV304 cells and the growth of B16 melanoma.Theclinical anti-tumour mechanism is considered to be related possibly to its anti-angiogenesis action byinhibiting the expression of KDR/FIK-1.
To investigate the anti-angiogenesis action of Taohong Siwu Decoction Ⅱ （THSWD Ⅱ）. Methods： The chick chorioallantoic membrane （CAM） assay was adopted to study the anti-angiogenesis action of THSWD Ⅱ; the MTT test was used to investigate its effect on proliferation of the human umbilical vein endothelial cells ECV304; and the immunohistochemical method was used to observe the effect of THSWD Ⅱ on the expression of kinase insert domain containing receptor/fetal liver kinase 1 （KDR/Flk-1） and the microvessel density （MVD） of B 16 melanoma in mice. Results： After treatment with THSWD Ⅱ, the blood vessel index of CAM and the absorbency of ECV304 in the THSWD Ⅱ 1mg/ml group and the 2mg/ml group decreased significantly （P〈0.01）; the weight, the expression of KDR/Flk-1 and the MVD of B16 melanoma in mice reduced significantly in the THSWD Ⅱ 5g/kg group, the 10g/kg group and the TSHSWD10g/kg plus cyclophosphamide group （P〈0.01）. Conclusion： THSWD Ⅱ has the actions of anti-angiogenesis, and inhibiting the proliferation of ECV304 cells and the growth of B16 melanoma. The clinical anti-tumour mechanism is considered to be related possibly to its anti-angiogenesis action by inhibiting the expression of KDR/FIK- 1.
